INTRODUCTION
The primary function of keratinocytes, which comprise 95% of the human epidermis, is to maintain the biochemical and physical integrity of the skin. It is now well accepted that they also play an important role in the skin's immune system [1] [2] [3] . Keratinocytes express and release immunomodulatory mediators in response to ultraviolet light, allergens, haptens, microbiological agents, and cytokines such as tumor necrosis factor (TNF)-α and interferon (IFN)-γ. The expression of various pro-inflammatory cytokines, chemokines, and adhesion molecules allow im-mune cells to enter the site of inflammation in the skin [4] [5] [6] .
TNF-α, a major pro-inflammatory cytokine, is produced by multiple cell types in the skin, including keratinocytes. It acts as a multifunctional cytokine, regulating the production of pro-inflammatory cytokines and chemokines such as interleukin (IL)-1β, IL-6, and IL-8, as well as adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1). In the skin, TNF-α also modulates the initial stages of the response to inflammation and injury [7] [8] [9] [10] . The stimulation of keratinocytes by TNF-α leads to the activation of various signaling pathways that involve caspases, nuclear factor-kappa B (NF-κB), and mitogen activated protein kinases (MAPKs), which subsequently increase the expression of inflammatory mediators 11 .
NF-κB is a protein transcription factor that is required for the transcription of a wide array of pro-inflammatory molecules that are thought to be important in the onset of apoptosis, in various autoimmune diseases, and in inflammation 12, 13 . In the resting state, NF-κB dimers are inactive in the cytoplasm of cells and are associated with the NF-κB inhibitory protein (I-κB). Upon stimulation with agents such as TNF-α, the IκB-kinase (IKK) complex is activated and phosphorylates IκB, leading to the substrate's ubiquitination and subsequent degradation. The resulting free NF-κB is translocated to the nucleus where it can activate target genes by binding to regulatory elements in the target gene's promoter [14] [15] [16] .
Rapamycin and mycophenolic acid (MPA) have potent immunosuppressive characteristics because they inhibit lymphocyte proliferation. At the molecular level, these drugs share several mechanistic similarities with other immunosuppressive drugs 17, 18 . Rapamycin, also known as sirolimus, is a macrocyclic triene antibiotic that was first isolated from Streptomyces hygroscopicus in the early 1970s. This drug forms an intracellular complex with FK506-binding protein 12 (FKBP12) and inhibits the activity of mammalian target of rapamycin (mTOR) 19, 20 .
MPA was initially marketed as mycophenolate mofetil (MMF), which has better oral bioavailability compared to that of its active metabolite, MPA 21 . MPA is a potent non-competitive inhibitor of inosine-monophosphate-dehydrogenase, and thus affects lymphocytes function by disabling the purine biosynthesis pathway. Recently, MPA has been used as a steroid treatment in immune-mediated disorders including immunoglobulin (Ig) A and psoriasis [22] [23] [24] .
We investigated the effects of different combinations of immunosuppressive drugs on the expression of pro-inflammatory mediators and found that the combination of rapamycin and MPA had a synergistically greater anti-inflammatory effect compared to that of single-drug treatments. 
MATERIALS AND METHODS

Materials
Cell culture of HaCaT cells
The human keratinocyte cell line (HaCaT) was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured at 37 o C in a humidified incubator containing 5% CO2 and 95% air in DMEM supplemented with 10% FBS (WelGENE Inc.) and antibiotics (100 U/ml penicillin G and 100 μg/ml streptomycin).
Reverse transcription-polymerase chain reaction
Total RNA was isolated from cells by using an RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The RNA (2 μg) was transcribed into cDNA using the PrimeScript 1st Strand cDNA Synthesis Kit (Takara, Otsu, Japan). The transcribed product was amplified by polymerase chain reaction (PCR) into a final volume of 50 μl by using the following sense and antisense primers (5′→3′): ICAM-1 sense, GGT GAC GCT GAA TGG GGT TCC; ICAM-1 antisense, GTC CTC ATG GTG GGG CTA TGA CTC; iNOS sense, TCC AAC CTG CAG GTC TTC GAT GC; iNOS antisense, GGA CCA GCC AAA and GAPDH sense, CAT GGG GAA GGT GAA GGT C; GAPDH antisense, TGG ACT CCA CGA CGT ACT CA. Amplification was performed using Taq polymerase (Takara, Otsu, Japan). The products were electrophoresed for 30 min at 100 V on 1% agarose gel. Gels were visualized using a Molecular Imager Gel Doc XR imaging system (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Western blot analysis
HaCaT cells were washed twice with ice-cold PBS and then lysed in RIPA buffer. The lysates were clarified by 30 min of centrifugation at 13,000 rpm at 4 o C. Total protein in the cell extracts or in the cytoplasmic and nuclear extracts was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 10% polyacrylamide gel. The separated proteins were transferred to a PVDF membrane and then the membrane was blocked with blocking buffer (5% skim milk in Tris-buffered saline containing 0.5% Tween 20) . Western blot analysis was performed by first incubating the membrane in target antibodies overnight at 4 o C, and then incubating them with horseradish peroxidase-conjugated secondary antibody. Detection of im- 
RESULTS
Cell viability after treatment with rapamycin, MPA or a combination of the two drugs in HaCaT cells
Cell viability was measured at different concentrations of rapamycin, MPA, or a combination of the two drugs by using MTT assay in HaCaT cells. HaCaT cells were incubated with various concentrations (10, 100, 1,000, or 5,000 nM) of rapamycin or MPA for 24 h (Fig. 1A) . Viability was not significantly altered by concentrations of rapamycin or MPA up to 1,000 nM. As shown Fig. 1B , the cells were also treated with a combination of different concentrations of rapamycin and MPA (Fig. 1C) . The combination of these agents did not show cytotoxicity.
Inhibitory effects of rapamycin and MPA on TNF-α-induced expression of pro-inflammatory genes in HaCaT cells
To compare the effect of a combination of rapamycin and MPA to that of either agent alone, the expression levels of TNF-α-induced pro-inflammatory genes such as IL-1β, IL-6, and IL-8 were measured using reverse transcription-PCR (RT-PCR) in HaCaT cells. HaCaT cells were pretreated with rapamycin, MPA, or a combination of rapamycin and MPA for 1 h, and then stimulated with TNF-α for 6 h. The expression of pro-inflammatory genes increased in TNF-α-stimulated HaCaT cells. The treatment of cells with rapamycin (100 nM) or MPA (100 nM) alone either slightly reduced or did not change the levels of IL-1β, IL-6, and IL-8 compared to the corresponding levels in the TNF-α-treated group. The treatment of cells with a combination of rapamycin (20 nM) and MPA (80 nM), or rapamycin (50 nM) and MPA (50 nM) only slightly reduced the level of pro-inflammatory gene expression, whereas rapamycin at 80 nM in combination with MPA at 20 nM strongly inhibited the levels of IL-1β, IL-6, and IL-8. An effect was not seen with any other single or combination treatment. Use of equal amounts of cDNA was confirmed on the basis of GAPDH expression (Fig. 2) .
Inhibitory effects of rapamycin and MPA on the phosphorylation of IκBα and the translocation of NF-κB p65 in HaCaT cells
NF-κB is a transcription factor for genes encoding inflammatory cytokines, chemokines, and inflammation-related factors 16 . To verify the effects of combinations of rapamycin and MPA on TNF-α-induced NF-κB signaling cascades, the phosphorylation of IκBα and the translocation of NF-κB were measured by performing western blot. Cells were pretreated with rapamycin (100 nM), MPA (100 nM), or a combination of both drugs for 1 h, before being stimulated with TNF-α. The activation of NF-κB molecules was analyzed using either nuclear extracts or whole-cell lysates. As shown in Fig. 3A , treatment with rapamycin or MPA slightly inhibited the phosphorylation of IκBα, and similar results were obtained from the combination of rapamycin (20 nM) and MPA (80 nM) or rapamycin (50 nM) and MPA (50 nM). However, in the presence of rapamycin (80 nM) and MPA (20 nM), the inhibition of TNF-α-induced phosphorylation of IκBα was much higher than that with any other treatment. Moreover, a combination of rapamycin (80 nM) and MPA (20 nM) inhibited the TNF-α-induced nuclear localization of NF-κB p65 in HaCaT cells when compared with individual drug treatments and other combinations of the two drugs. These results suggest that the combination of rapamycin (80 nM) and MPA (20 nM) has an inhibitory effect on the The phosphorylation of substrates in the MAPK family (ERK, p38, JNK) was detected by western blot analysis using specific antibodies. The densities of protein expression were expressed as percentages of protein density in the TNF-α-only group. *p＜0.05 and **p＜0.01 versus the TNF-α-treated group. The densitometric analysis of the western blot was standardized using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control.
signaling pathway that leads to the activation of NF-κB in TNF-α-treated HaCaT cells.
Inhibitory effects of rapamycin and MPA on TNF-α-induced activation of ERK, p38, and JNK MAPKs in HaCaT cells
In order to assess the effects of a combination of these drugs on TNF-α-induced MAPK activation in HaCaT cells, we performed western blot analysis. We compared the inhibitory effects of a single drug or a combination of both drugs on the MAPK signaling pathway. As shown in Fig.  3B , in the presence of a combination of 80 nM rapamycin and 20 nM MPA, the inhibition of TNF-α-induced ERK activation was markedly higher than that in the presence of a combination of 50 nM rapamycin and 50 nM MPA. Single-drug treatment and the combination of 20 nM rapamycin and 80 nM MPA did not inhibit TNF-α-induced ERK activation. TNF-α-induced p38 activation decreased in the MPA-only treatment group and in the combination groups but not in the rapamycin-only treatment group.
Inhibitory effects of rapamycin and MPA on TNF-α-induced ICAM-1 and iNOS expression in HaCaT cells
To investigate the synergistic inhibitory effects of a combination of rapamycin and MPA on TNF-α-induced ICAM-1 and iNOS expression, RT-PCR and western blot analysis were performed. After TNF-α treatment in HaCaT cells, the HaCaT cells were treated with rapamycin and MPA alone, as well as with a combination of the two drugs. Following treatment, the levels of ICAM-1 and iNOS were measured by RT-PCR and western blot. TNF-α-induced ICAM-1 and iNOS expression in HaCaT cells was slightly suppressed by rapamycin and MPA. The co-treatment of rapamycin and MPA resulted in significantly greater inhibition compared to that with single-drug treatments. The greatest inhibitory effect was achieved with a combination of 80 nM rapamycin and 20 nM MPA (Fig. 4A ).
In addition, we used pharmacological inhibitors of MAPK to investigate the functional relationship between MAPK activation and ICAM-1 expression. TNF-α-induced ICAM-1 expression was slightly suppressed in HaCaT cells with ERK, p38, and JNK inhibitors. These results suggest that the activation of ERK, p38, and JNK is involved in TNF-α -induced ICAM-1 expression, and the combination of rapamycin (80 nM) and MPA (20 nM) modulates signaling cascades that involve TNF-α-induced activation of ERK and p38 but not JNK (Fig. 4B ).
DISCUSSION
Many immunosuppressive drugs are currently being used clinically, including cyclosporine, FK-506, rapamycin, and MPA 25, 26 . Rapamycin has been used in the treatment of various pathophysiological conditions including nephrotoxicity, hypertension, ischemia, glutamate neurotoxicity, autoimmune diseases, and inflammatory diseases, by regulating the expression of nitric oxide and prostaglandin E2 [27] [28] [29] [30] . MPA can induce the apoptosis of activated T-lymphocytes by depleting guanosine nucleotides, and suppress the expression and function of adhesion molecules required for the recruitment of lymphocytes and monocytes to sites of inflammation 31, 32 .
Recently, synergistic or additive effects of combined treatments with rapamycin and MPA in various pathological conditions have been reported in several studies. Various studies suggest possible synergistic effects of a combination of rapamycin and imatinib on tuberous sclerosis complex neoplasia 33 , rapamycin and LY294002 in melanoma cells 34 , and rapamycin and cyclosporine A in an autoimmune disease model 35 .
In the present study, we found that the combination of rapamycin and MPA can synergistically inhibit pro-inflammatory reactions and molecular regulatory mechanisms in TNF-α-stimulated HaCaT cells. There are many reports that an increase in the expression of nitric oxide and adhesion molecules such as ICAM-1 in keratinocytes plays an important role in diseases involving skin inflammation 6, 36, 37 . Our results indicate that a combination of rapamycin and MPA can inhibit TNF-α-induced ICAM-1 and iNOS expression in HaCaT cells. Interestingly, the combination of 80 nM rapamycin and 20 nM MPA resulted in significantly greater suppression than that achieved with single-agent treatments and combinations with different doses. We also observed a decrease in the expression of pro-inflammatory cytokines and chemokines in TNF-α-induced HaCaT cells. This suggests that the anti-inflammatory effect of the combination of rapamycin and MPA is mediated by blocking the activation of NF-κB and the phosphorylation of ERK and p38 MAPK, which inhibits the expression of pro-inflammatory genes induced by TNF-α.
In conclusion, the findings of the present study demonstrate that a combination of rapamycin and MPA synergistically inhibits the expression of pro-inflammatory factors in TNF-α-induced HaCaT cells. These findings indicate that the inhibition of ICAM-1 expression might cause the blockade of IL-6 or IL-8 expression through inhibition of ERK, P38, and NF-κB signaling pathways by rapamycin and MPA. The use of lower concentrations of rapamycin and MPA are expected to reduce the occurrence of side effects and toxicity. The different anti-inflammatory mechanisms of rapamycin and MPA appear to result in a synergistic effect when the two drugs are used in combination. However, the interactions of these two immunosuppressive drugs are still being examined, and additional evaluations with other types of immune cells and in vivo trials are needed.
